Skip to main content
. Author manuscript; available in PMC: 2022 Jul 21.
Published in final edited form as: J Commer Biotechnol. 2022 Jul 17;27(2):5–13. doi: 10.5912/jcb1020

Figure 5:

Figure 5:

Percentage of collaborations and agreement types for early-stage drug development companies. (A) NCI TTC-mediated collaboration among NIH-funded early-stage drug development companies. (B) Licenses and collaboration agreements with early-stage drug development companies. (C) Percentage of NCI TTC-mediated collaboration of early-stage drug development companies with either a Successful or Unsuccessful Outcome. (D) Fold change in the collaboration effort of early-stage drug development companies with either a Successful or Out of Business status.